Geode Capital Management LLC Has $254.19 Million Stock Position in Charles River Laboratories International, Inc. $CRL

Geode Capital Management LLC lifted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 0.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,276,502 shares of the medical research company’s stock after purchasing an additional 9,756 shares during the quarter. Geode Capital Management LLC owned approximately 2.59% of Charles River Laboratories International worth $254,186,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Tema Etfs LLC bought a new stake in shares of Charles River Laboratories International during the 4th quarter worth $26,000. Rothschild Investment LLC boosted its holdings in shares of Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after buying an additional 84 shares during the period. Atlantic Union Bankshares Corp bought a new stake in shares of Charles River Laboratories International during the 3rd quarter worth $31,000. Activest Wealth Management boosted its holdings in shares of Charles River Laboratories International by 10,900.0% during the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock worth $44,000 after buying an additional 218 shares during the period. Finally, Geneos Wealth Management Inc. boosted its holdings in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock worth $44,000 after buying an additional 145 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on CRL. Evercore reaffirmed an “outperform” rating and set a $220.00 price objective on shares of Charles River Laboratories International in a report on Friday, May 8th. JPMorgan Chase & Co. decreased their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Monday, April 13th. TD Cowen reduced their price target on shares of Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating for the company in a report on Friday, February 20th. Wall Street Zen downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Weiss Ratings raised shares of Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. Eleven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $208.50.

Charles River Laboratories International Trading Down 4.1%

Shares of CRL stock opened at $174.56 on Wednesday. Charles River Laboratories International, Inc. has a 52-week low of $132.65 and a 52-week high of $228.88. The stock has a market cap of $8.41 billion, a price-to-earnings ratio of -46.43, a P/E/G ratio of 2.08 and a beta of 1.46. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The firm has a fifty day moving average of $169.66 and a 200-day moving average of $181.34.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company had revenue of $995.83 million during the quarter, compared to analysts’ expectations of $977.46 million. During the same quarter in the prior year, the company posted $2.34 EPS. The business’s revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 11.04 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.